Lucinactant

DRUG3 trials

Sponsors

Windtree Therapeutics

Conditions

Acute Hypoxemic Respiratory FailureAcute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)COVID-19Meconium Aspiration

Phase 2

Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old

CompletedNCT00578734

Windtree TherapeuticsAcute Hypoxemic Respiratory Failure

Start: 2007-06-30End: 2010-04-30Updated: 2012-05-03

The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)

CompletedNCT04389671

Windtree TherapeuticsAcute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), COVID-19

Start: 2021-01-05End: 2022-02-20Updated: 2023-06-23

Phase 3

Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome

TerminatedNCT00004500

Windtree TherapeuticsMeconium Aspiration

Start: 2000-03-31End: 2004-11-30Updated: 2012-05-03